The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives
N Dookie, SL Ngema, R Perumal… - Clinical Microbiology …, 2022 - Am Soc Microbiol
Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …
Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB drugs
Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …
Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR …
AHXP Chan Kwong, EAM Calvier, D Fabre… - … of Pharmacokinetics and …, 2020 - Springer
Population pharmacokinetic analysis is used to estimate pharmacokinetic parameters and
their variability from concentration data. Due to data sparseness issues, available datasets …
their variability from concentration data. Due to data sparseness issues, available datasets …
The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs
Abstract Background In South Africa, an estimated 11% of the population have high alcohol
use, a major risk factor for TB. Alcohol and other substance use are also associated with …
use, a major risk factor for TB. Alcohol and other substance use are also associated with …
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment
Rationale: Standardized dosing of antitubercular drugs contributes to a substantial
incidence of toxicities, inadequate treatment response, and relapse, in part due to variable …
incidence of toxicities, inadequate treatment response, and relapse, in part due to variable …
N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment
T Mthiyane, J Millard, J Adamson… - Antimicrobial agents …, 2020 - Am Soc Microbiol
The distribution of N-acetyltransferase 2 gene (NAT2) polymorphisms varies considerably
among different ethnic groups. Information on NAT2 single-nucleotide polymorphisms in the …
among different ethnic groups. Information on NAT2 single-nucleotide polymorphisms in the …
Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients
Rifampin (RF) is metabolized in the liver into an active metabolite 25-desacetylrifampin and
excreted almost equally via biliary and renal routes. Various influx and efflux transporters …
excreted almost equally via biliary and renal routes. Various influx and efflux transporters …
Machine learning approach in dosage individualization of isoniazid for tuberculosis
BH Tang, XF Zhang, SM Fu, BF Yao, W Zhang… - Clinical …, 2024 - Springer
Introduction Isoniazid is a first-line antituberculosis agent with high variability, which would
profit from individualized dosing. Concentrations of isoniazid at 2 h (C2h), as an indicator of …
profit from individualized dosing. Concentrations of isoniazid at 2 h (C2h), as an indicator of …
Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of …
Purpose Significant pharmacokinetic variabilities have been reported for isoniazid across
various populations. We aimed to summarize population pharmacokinetic studies of …
various populations. We aimed to summarize population pharmacokinetic studies of …
[HTML][HTML] Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure
PQ Hoa, HK Kim, TW Jang, H Seo, JY Oh… - International Journal of …, 2024 - Elsevier
Background Rifampicin (RIF) exhibits high pharmacokinetic (PK) variability among
individuals; a low plasma concentration might result in unfavorable treatment outcomes and …
individuals; a low plasma concentration might result in unfavorable treatment outcomes and …